BioPharmSignal logoBioPharmSignal

Biotech News

AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)

AN2 Therapeutics (ANTX)AN2 TherapeuticsPartnership

AN2 awarded third year of funding from Gates Foundation MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 10, 2025-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics through its boron chemistry platform, today announced a collaboration

Open original release

Related news

ANTXAN2 Therapeutics2026-03-03 21:00 EST

AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)

SCYXSCYNEXIS2025-11-17 15:15 EST

Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections

ANTXAN2 Therapeutics2026-06-04 11:00 EST

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

OGENOragenics2026-05-07 12:30 EST

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

VIRIVirios Therapeutics2026-04-23 13:00 EST

Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M

OGENOragenics2025-10-07 12:30 EST

Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

ASMBAssembly Biosciences2025-12-22 13:00 EST

Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

ABUSArbutus2025-06-25 11:30 EST

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

SPROSpero Therapeutics2025-03-18 08:00 EST

Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

SPROSpero Therapeutics2024-11-07 16:05 EST

Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024

View all latest news

AN2 Therapeutics

AN2 Therapeutics is an infectious-disease company focused on novel anti-infective medicines. Its platform is aimed at serious bacterial and related infectious conditions where new options matter.

Recent company news

ANTXAN2 Therapeutics2026-06-04 11:00 EST

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

ANTXAN2 Therapeutics2026-05-21 11:00 EST

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

ANTXAN2 Therapeutics2026-05-11 20:01 EST

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

ANTXAN2 Therapeutics2026-05-07 20:01 EST

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

ANTXAN2 Therapeutics2026-03-31 11:00 EST

AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

Stock data

Close
4.93 USD
Market cap
146.59M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States